stars 1 stars 2 stars 3

CYTOO is a preclinical stage drug discovery company specialized in muscular and neuromuscular disorders. CYTOO partners its versatile patient-derived muscle drug discovery engine to pharma and biotech companies and develops its own drug candidates. CYOO has developed a fully mature human in vitro muscle model (MyoScreen) derived from primary human samples (healthy and pathological myoblasts) for generating NCEs from a variety of pathological conditions (rare, chronic). Core expertise lies on in vitro muscle regeneration, contraction, hypertrophy, and metabolism.

CYTOO Questions

The CYTOO annual revenue was $1 million in 2026.

Marc Liberatore is the CEO of CYTOO.

20 people are employed at CYTOO.

The NAICS codes for CYTOO are [5417, 541713, 541, 54, 54171].

The SIC codes for CYTOO are [87, 873].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users